PCSK9 and coronary artery disorder: However, the three UK Biobank participants (‘human double knock-outs’) who carried both, PCSK9 and APOB PTVs, showed on average a further reduction in plasma LDLc by 41.2 mg/dl compared to individuals with PTVs in only one of the two genes, and by 91.7 mg/dl compared to individuals with no PTV in either of the two genes (Fig. 1b, Supplementary Fig. 1a), suggesting considerable additional protection from CAD.